GRI (GRI Bio) Moat Score: 2/10 (As of Aug. 19, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GRI GRI Bio Inc GRI
33 GF Score
Price $1.72
! 1 Warning Sign
View Full Analysis

What is GRI Bio Moat Score?

GRI Bio GRI -1.16% 33 Moat Score is 2 as of Aug. 19, 2026. GuruFocus rates GRI with a GF Score™ of 33/100. The stock has 1 warning sign investors should review. Among 1,388 Biotechnology companies, GRI Bio ranks better than 58.43% on this metric.

GRI Bio has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

GRI Bio has No Moat: GRI Bio Inc lacks significant market leadership, network effects, or strong intellectual property. The company does not exhibit durable cost advantages or significant regulatory barriers, resulting in a very weak competitive position.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes GRI Bio might have No Moat - Very weak/transient advantages.

GRI Bio  (NAS:GRI) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

GRI Bio Moat Score Related Terms

GRI vs ISCO, VRAX, SLXN: Moat Score Comparison

For the Biotechnology subindustry, GRI Bio's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GRI Bio Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GRI Bio's Moat Score distribution charts can be found below:

* The bar in red indicates where GRI Bio's Moat Score falls into.


GRI
33GF Score
GRI Bio Inc GRI
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
GRI Bio (GRI) has a Moat Score of 2 as of Aug. 19, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, GRI Bio ranks #577 out of 1388 companies in the Biotechnology industry, placing it in the top 41.6%.
Is GRI Bio's Moat Score too high?
GRI Bio's current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. GRI Bio's value of 2 is 0% at this industry median. Based on the distribution chart, GRI Bio ranks #577 out of 1388 companies in the Biotechnology industry, which is above the industry midpoint. Overall, GRI Bio has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does GRI Bio's Moat Score compare to ISCO and VRAX?
According to the Biotechnology industry distribution chart, GRI Bio ranks #577 out of 1388 companies for Moat Score. This puts GRI Bio in the upper half of its industry. The industry median Moat Score is 2.00. GRI Bio's value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,388 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. GRI Bio's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. GRI Bio's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GRI Bio stock overvalued right now?
GRI Bio (GRI) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. GRI Bio's overall GF Score™ is 33/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For GRI Bio (GRI), the current Moat Score is 2 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

GRI Bio Business Description

Address 2223 Avenida De La Playa, Suite 208, La Jolla, CA, USA, 92037
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
33GF Score

Get the complete analysis for GRI

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.72
Price